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Abstract
Corticotropin releasing factor (CRF) is the key coordinator of the neuroendocrine and behavioral
responses to stress. In the central nervous system, CRF excites select neuronal populations, and
infusion of CRF into the cerebral ventricles of infant rats produces severe age-dependent limbic
seizures. These seizures, like other CRF effects, result from activation of specific receptors. Both
of the characterized members of the CRF receptor family (CRF1 and CRF2), are found in the
amygdala, site of origin of CRF-induced seizures, and may therefore mediate these seizures. To
determine which receptor is responsible for the excitatory effects of CRF on limbic neurons, a
selective, non-peptide CRF1 antagonist was tested for its ability to abolish the seizures, in
comparison to non-selective inhibitory analogues of CRF. Pretreatment with the selective CRF1
blocker (NBI 27914) increased the latency and decreased the duration of CRF-induced seizures in
a dose-dependent manner. The higher doses of NBI 27914 blocked the behavioral seizures and
prevented epileptic discharges in concurrent electroencephalograms recorded from the amygdala.
The selective CRF1 blocker was poorly effective when given systemically, consistent with limited
blood-brain barrier penetration. Urocortin, a novel peptide activating both types of CRF receptors
in vitro, but with preferential affinity for CRF2 receptors in vivo, produced seizures with a lower
potency than CRF. These limbic seizures, indistinguishable from those induced by CRF, were
abolished by pretreatment with NBI 27914, consistent with their dependence on CRF1 activation.
In summary, CRF induces limbic seizures in the immature rat, which are abolished by selective
blocking of the CRF1 receptor. CRF1-messenger RNA levels are maximal in sites of seizure origin
and propagation during the age when CRF is most potent as a convulsant. Taken together, these
facts strongly support the role of the developmentally regulated CRF1 receptor in mediating the
convulsant effects of CRF in the developing brain.
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1. Introduction
Corticotropin releasing factor (CRF) is a 41 amino acid neuropeptide which activates target
pituitary cells and neurons via specific membrane receptors [16,38]. CRF release during the
hormonal response to stress induces the secretion of corticotropin (ACTH) from the
pituitary, an action blocked by analogues which compete for the receptors [33,39] In the
central nervous system (CNS), CRF mediates ‘central’ components of the stress response,
activating neurons in the amygdala as well as locus ceruleus, hippocampus and cerebellum
[1,20,21,40]. In the immature rat, synthetic CRF excites hippocampal neurons [35] and
produces prolonged limbic seizures [3,7]. Electroencephalographic (EEG) mapping has been
used to localize the origin of these seizures to the amygdala [4], and propagation of the
seizures to the hippocampus has been demonstrated. The postsynaptic mechanisms of the
limbic seizures induced by CRF, and the reason for the increased convulsant potency of the
peptide during development have not been established.
CRF activates postsynaptic receptors on target neurons [16,22]. Two members of the CRF
receptor family are currently known, and consist of membrane-spanning G-protein coupled
molecules [14,27,30]. The first, CRF1, is found in the CNS and the pituitary [32,44], and is
the candidate mediator for many of the endocrine effects of CRF. The second receptor,
CRF2, is found in at least two splice forms in the rat (CRF2α and CRF2β ; [27,28]). One of
these subtypes, CRF2α, is found primarily in the CNS. Although the messenger ribonucleic
acid (mRNA) distribution patterns for CRF1 and CRF2 in the adult rat brain are quite
distinct, both genes are expressed in limbic neurons of the amygdala and the hippocampus
[13]. Therefore, both types of CRF receptor are candidates for mediating the convulsant
effects of CRF. In the developing rat brain, CRF receptors have been demonstrated in the
amygdala and hippocampus via binding assays [24,31]. Recently, CRF1-mRNA has been
localized to the amygdala and hippocampus of the developing rat [2].
The goal of this study was to determine the receptor type that is responsible for mediating
the excitatory effects of CRF on limbic neurons. The study compared the effects of a novel,
selective CRF1 blocker and of established non-selective CRF1/CRF2 receptor antagonists on
the behavioral and electrographic seizures induced by CRF. In addition, the convulsive
effects of a second endogenous ligand for both types of CRF receptor, urocortin, were
eliminated by selective blocking of CRF1.
2. Materials and methods
2.1. Animals
Infant rats (n = 185) were offspring of time-pregnant, Sprague–Dawley rats. They were born
in the University of California, Irvine (UCI) federally approved animal facility, kept on a 12
h lightrdark cycle (lights on at 07.00). and given access to unlimited food and water. The
time of birth of pups was determined every 12 h, and the day of birth was considered day 0.
Litters were culled to 12 pups and mixed among experimental groups. Thus, for each
experiment, controls were littermates of, or precisely age-matched, to the experimental
groups. Cages were maintained in a quiet, uncrowded room. Pups were implanted with
stainless steel cannulae directed to the right cerebral ventricle 24 h prior to experiments.
Cannulation was carried out under halothane anesthesia, using a stereotaxic apparatus, as
described in detail elsewhere [3,4,7,8,10] and cannula position was verified in all cases [4].
Peptide infusion was carried out on postnatal days 9–13, but each experiment consisted of a
comparison of experimental and control pups on the same day of life. Each pup was
subjected to CRF or urocortin administration into the cerebral ventricle (i.c.v.), with or
without a receptor antagonist, once only [4].
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2.2. Materials
CRF, α-helical CRF9–41 and [D-Phe12,Nle21,38,C-MeLeu37]CRF12 – 41 (i.e., D-Phe-
CRF12 – 41), were purchased from Bachem (Torrance, CA). NBI 27914 was synthesized at
Neurocrine Biosciences as described elsewhere [15]. Urocortin was a generous gift from Dr.
Nicholas Ling (Neurocrine Biosciences).
Peptides were dissolved in distilled water containing a dye marker (Fast Green, Sigma, St.
Louis, MO). Final concentrations were 0.15 nmolrml for CRF and 0.5 nmol/μl for the
peptide antagonists. Urocortin was diluted to 2 μg/μl or 1 μg/μl. NBI 27914 was dissolved
in dimethyl sulfoxide (DMSO) at a final concentration of 10 μg/μl for i.c.v. administration,
and 20 μg/μl for systemic administration. Control vehicles consisted of the dye-water
solution for CRF, α-helical CRF and urocortin, and dye-DMSO for NBI 27914.
2.3. Experimental design
2.3.1. Experiment 1. Does i.c.v. administration of a specific CRF1 blocker
eliminate CRF-induced seizures? How does NBI 27914 compare with a peptide
CRF1/CRF2 receptor antagonist?—Experimental groups (n = 5–12) received NBI
27914 or a non-selective CRF1/CRF2 antagonist 15–20 min prior to CRF infusion, while
controls received vehicle. Drugs were administered i.c.v. via the indwelling cannula using a
micro-infusion pump, while the pups were freely moving on a warming pad (34°C)
[3,4,7,8]. The CRF dose (0.15 nmol in 1 μl) was chosen to result in significant (2–3 h long)
seizures with a short latency. Subsequent to the infusion of CRF, seizure latency and
duration were monitored for a minimum of 180 min. Animals were scored at 5 min intervals
for the behavioral limbic seizures induced by CRF using the previously established
methodology [3,4,8].
2.3.2. Experiment 2. Does NBI 27914 block CRF-induced seizures when given
systemically?
2.3.2.1. Intraperitoneal (i.p.) administration: The experimental group (n = 12) received
the selective CRF1 receptor blocker i.p., using a 1 ml tuberculin syringe. Based on pilot
experiments and on previous studies of CRF antagonists [10]
,
 the injections were carried out
either 15–20 min or 30–40 min prior to CRF infusion. The dose tested was 10 mg/kg.
Control rats received an equal volume of DMSO.
2.3.2.2. Oral administration: Experimental animals received NBI 27914 (20 mg/kg) by
gavage, using a 1 ml tuberculin syringe attached to a pre-calibrated polyethylene tube. In
pilot experiments, the administration of a DMSO-dye solution via the tube resulted in
obvious staining of stomach contents. Because of the persistence of dye in the gastric cavity
for at least 2 h, the compound was administered 0.5, 1 or 2 h prior to the CRF infusion.
2.3.3. Experiment 3. Does a CRF1 receptor blocker elimi-nate the epileptic
EEG correlates of seizures induced by CRF?—For EEG recordings, a separate
group of rats (n = 6) was implanted with bipolar electrodes directed to the amygdala and
dorsal hippocampus, using previously established methods [4,5]. Briefly, pups were
subjected to halothane anesthesia and placed in an infant rat stereotactic apparatus (Kopf
Instruments, Tujunga, CA). Electrodes were implanted using age-appropriate coordinates
[4], and were aimed at the basal amygdala and/or dorsal hippocampus. Each animal carried
amygdala – or amygdala and hippocampus – electrode arrays in addition to the i.c.v.
cannulae. The placement of the electrode tips was verified for each animal at the end of the
experiment as described elsewhere [4]. EEGs were recorded using a GRASS 78E polygraph,
connected via long, flexible wires to freely moving animals on a warming pad, as described
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elsewhere [3–5]. All infusions were given i.c.v. and carried out at 08.00–10.00 h, to avoid
the effects of circadian variability in endogenous CRF [43].
2.3.4. Experiment 4. Can limbic seizures be generated by activation of CRF
receptors by the novel agonist, urocortin? Do the seizures persist upon
blocking CRF1 by NBI 27914?—Four experimental groups (on postnatal days 10 and
11) were evaluated for the presence, latency, duration and phenomenology of limbic
seizures. Twelve pups received 0.15 nmol of urocortin i.c.v., and the other twelve were
infused i.c.v. with 0.75 nmol of urocortin. Half of the animals in each group were pretreated
with NBI 27914 (1 mg/kg. 20 min prior to urocortin administration.
Statistical analysis was performed using non-parametric tests (Mann–Whitney unpaired two-
tailed comparison, INSTAT software) without assumptions regarding the distribution of
values.
3. Results
NBI 27914 given i.c.v. increased the latency to the onset of CRF-induced seizures and
decreased their duration in a dose-dependent manner (Table 1, Fig. 1). As is evident from
the table, increasing doses of NBI 27914 (0.33, 0.67 and 1.0 mg/kg) abolished the seizures
entirely in 40, 62.5 and 67% of rats, respectively. In comparison, the i.c.v. pre-
administration of the non-selective CRF receptor blocker α-helical CRF9 – 41 eliminated
CRF-induced seizures in 33% of the animals. In rats implanted with depth electrodes, pre-
administration of NBI 27914 prevented the development of epileptic discharges in EEG
recordings from the amygdala (Fig. 2).
The effect of intraperitoneally (i.p.) administered NBI 27914 on CRF-induced seizures was
highly dependent on the time of administration relative to that of CRF infusion. As is
evident from Table 2, an interval of 15–20 min did not alter any parameter of CRF-induced
seizures significantly. Seizure latency (10.0 ± 1.0 min) and duration (129.0 ± 27.4 min) did
not differ from control values (8.5 ± 1.3 and 138.8 ± 9.9 min). However, an interval of 30–
40 min prior to CRF infusion permitted NBI 27914 given i.p. to markedly increase the
latency (23.5 ± 3.6 min; P = 0.0008) and decrease the duration (104.8 ± 5.8; P = 0.018) of
seizures induced by CRF. In comparison, i.p. administration of two doses of α-helical
CRF9 – 41 did not diminish the duration or increase the latency of CRF-induced seizures
(Table 2). The higher dose tested, 4.0 mg/kg, was administered either 20 or 40 min prior to
CRF. The time to the onset of the seizures (12.8 ± 3.5 and 8.0 ± 1.6 min) and their duration
did not differ between the 20 min and 40 min groups (P = 0.31, Mann–Whitney U-test).
Therefore, the data for these groups were combined in Table 2.
Oral administration of NBI 27914 to suckling rats resulted in a highly variable rate and
extent of absorption and penetration into the CNS. Thirty minutes did not suffice to allow
the compound to reach CRF receptors (Table 3). Elimination of the seizures or a significant
decrease in their duration were noted upon administration of NBI 27914 1 h prior to CRF
infusion. When the CRF1 blocker was given 120 min prior to the convulsant challenge, a
marked inter-animal variability was observed. Three pups had no seizures, but the other
three had no evident effect of the antagonist, with a short latency (Table 3) and prolonged
duration (180 min) of the seizures.
Urocortin administration to immature rats resulted in the development of behavioral limbic
seizures, but with a longer latency and significantly shorter duration than those produced by
equivalent doses of CRF (Table 4). Pre-administration of NBI 27914 practically eliminated
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the effects of the lower dose of urocortin, while seizures induced by the higher dose were
significantly attenuated (P = 0.02 vs. the group not receiving NBI 27914, Table 4).
4. Discussion
The current study demonstrates that a selective competitive antagonist of the CRF1 receptor
type abolishes the neuronal excitation effect of CRF in developing rats. The behavioral and
electroencephalographic seizures induced by CRF in neonatal (first postnatal week) and
infant (second postnatal week) rats have been described and characterized previously
[3,4,7,8]. CRF leads to seizures that originate in the amygdala and spread to other limbic
structures [4]. The doses required for seizure production (picomolar range) are insufficient
to activate the pituitary, and do not increase plasma glucocorticoids [3]. Elevation of plasma
corticosterone is only evident after the onset of the seizures which are clearly a major
activator of the stress response. CRF-induced seizures are therefore a paradigm of the
central effects of the peptide on its receptor(s). The seizures can be eliminated by non-
selective CRF1/CRF2 receptor antagonists, but not by, for example, glutamate receptor
antagonists [3,9,10].
Administration of the selective CRF1 receptor blocker, NBI 27914, into the lateral cerebral
ventricle of infant rats led to a dose-dependent attenuation of CRF-induced seizures. The
higher doses tested were at least as potent as non-selective peptide CRF1/CRF2 antagonists.
These data are strongly consistent with the assignment of the CRF1 as the receptor
mediating the excitatory, convulsant effects of CRF.
Several additional lines of evidence further support CRF1 activation as a prerequisite for
neuronal excitation by CRF. First, CRF-induced seizures involve the amygdala and
hippocampus [4], areas expressing high levels of CRF1-mRNA [13]. Moreover, CRF has
been demonstrated to have a highly age-dependent convulsant potency, which peaks during
the second postnatal week [4,7]. The developmental profile of the CRF1-mRNA in the
hippocampus and amygdala mirrors the pattern of the peptide's potency. Maximal levels of
steady-state CRF1-mRNA are found during the second postnatal week, potentially
accounting for the enhanced excitatory effects of the peptide during this period [2].
An intriguing question is whether activation of CRF1 is involved in, or is required for, other
limbic seizures generated in the developing rat during the second postnatal week. In our
hands, seizures induced during this period by i.p. administration of kainic acid are not
modified by pretreatment with peptide, non-selective blockers of both CRF receptors
(Baram and Schultz, unpublished observations). However, using a model for febrile seizures
[11], the administration of non-selective CRF receptor blockers prior to exposure to
hyperthermia results in elevation of the threshold temperature at which seizures occur [6].
This is consistent with a role for CRF receptor activation in the mechanism of generating
febrile seizures which are highly age-specific developmental seizures [6].
The selective CRF1 inhibitor blocked CRF-induced seizures reliably when administered into
the lateral cerebral ventricles. Systemic administration suggested either an erratic absorption
from both the peritoneal and gastric cavities, or poor penetration of the blood-brain barrier.
Prolonging the interval between intraperitoneal administration and the CRF challenge
resulted in attenuation of CRF-induced seizures at doses approximately 30-fold higher than
those yielding a comparable effect when given i.c.v. This suggests that some of the
systemically given NBI 27914 did penetrate the blood-brain barrier of the immature rat.
Conversely, peptide inhibitory analogues of CRF given systemically did not alter any
parameter of the CRF-induced seizures. This finding is consistent with either a rapid
degradation of the peptides, or their inability to penetrate the blood-brain barrier.
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CRF binds the CRF1 receptor with a higher affinity than the CRF2 receptor type [27].
Recently, a CRF-related peptide, urocortin, has been characterized [41]
,
 which demonstrates
comparable affinities to both types of CRF receptors in vitro [18]. Because of its relatively
high affinity for CRF2, it has been suggested that urocortin might be the ‘native ligand’ of
this receptor [27]. Indeed, in vivo, urocortin is a far more potent anorexia-inducing agent
than CRF: the median effective dose was 0.19 μg for urocortin and 6.82 μg for CRF.
Suppression of food intake is generally considered to depend on activation of CRF2
receptors in the hypothalamic ventromedial nucleus [36]. Conversely, urocortin was
approximately 20-fold less potent than CRF in producing ‘anxiety’-type behaviors [36].
Using the in vivo paradigm described in the present study, urocortin initiated behaviors that
were indistinguishable from those produced by CRF. However, based on the duration of
seizures induced by 0.15 and 0.75 nmol of urocortin (Table 4) the potency of this peptide in
neuronal excitation was only about 20% of that of CRF. In addition, inhibiting the activation
of the CRF1 receptor by urocortin using NBI 27914 essentially eliminated the effects of
urocortin in this paradigm, which is highly suggestive of the mediation of these excitatory
actions by the CRF1 receptor type.
CRF is emerging as an important neuromodulator in several CNS regions [34] which may
have significant clinically relevant effects [17,29,37]. For example, the peptide induces
protein phosphorylation in the hippocampus [23] and may enhance learning and memory
[12,26]. CRF, probably via effects at amygdala receptors, is also highly anxiogenic
[19,25,42], and leads to appetite suppression. In the developing brain, CRF is a potent
convulsant, probably via actions on receptors in the amygdala and hippocampus [2,4]. The
presence of at least two types of CRF receptors raises the possibility of selective
enhancement of desired effects of CRF and abrogation of its detrimental actions. The
assignment of the neuroexcitant actions of CRF to CRF1 thus offers an opportunity for the
development of potentially clinically useful drugs which directly and selectively modulate
the activation of this receptor.
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Fig. 1.
Dose effect of pretreatment with NBI 27914 on the duration of seizures evoked by CRF. Rat
pups received the selective CRF1 inhibitor at the doses indicated on the x-axis (see Section
2.3.1). Values are means ± S.E.M. *Significantly different from control values, P-0.05; **
P-0.01 (Mann–Whitney U-test).
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Fig. 2.
Effects of pretreatment with NBI 27914 on EEG features of seizures induced by CRF. Six
immature rats were implanted with bipolar electrodes directed at the left amygdala on the
10th postnatal day (see text). Depth EEGs were recorded on the following morning. Panel A
shows low-voltage, non-rhythmic background activity in all six tracings (1–6). Occasional
brief movement artifacts are noted by the arrows. Panel B was obtained 30 min after the
administration of 1 mg/kg of NBI 27914 to rats Nos. 2, 3 and 6, and 13–15 min after the
infusion of 0.15 nmol CRF to all six pups. The EEG features of animals Nos. 2, 3 and 6
reveal only increased overall frequency of movement artifacts. High-voltage spike-wave and
polyspike epileptic discharges are evident in rats subjected to CRF without pretreatment
with NBI 27914 (curved arrows). Behavioral limbic seizures lasted for 150, 180 and 110
min in rats Nos. 1, 4 and 5, respectively. No behavioral seizures were observed in rats Nos.
3 and 6. Rat No. 2 had one episode of wet dog shakes, and a seizure lasting 25 min.
Horizontal marker indicates 1 s; vertical marker corresponds to 50 μV.
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Table 1
Effect of NBI 27914 and non-selective CRF receptor antagonists on the latency of CRF-induced seizures
Receptor blocker Dose (mg/kg) Group size (n) Latency of seizures (min)
None 23 9.96 ± 1.10
NBI 27914 0.33 7 2 = no seizures
5 = 29.40 ± 3.53 *
0.67 8 5 = no seizures
3 = 30.67 ± 3.33 *
1.0 3 2 = no seizures
1 = 59 min latency
α-Helical CRF9–41 0.5 12 4 = no seizures
8= 21.4 ± 4.4 *
D-Phe-CRF12–41 0.25 11 1 = no seizures
10= 41.3 ± 11.8 *
Animals received the indicated CRF antagonist or vehicle 15–20 min prior to the infusion of 0.15 nmol of CRF, via an i.c.v. cannula. Latency and
duration of seizures were scored as described in the text.
*Statistically different from control (P < 0.001, two-tailed Mann–Whitney U- test).
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Table 3
Effect of oral NBI 27914 on CRF-induced seizures
Group Interval to CRF (min) n Seizure latency (min) Seizure duration (min)
Control Not-applicable 17 9.6 ± 1.8 125.3 ± 12.8
NBI 27914 30 3 9.0 ± 1.0 123.3 ± 6.0
60 6 2 = no seizures 53.3 ± 27.9 *
4= 20.2 ± 8.6
120 6 3 = no seizures 77.5 ± 35.4
3= 8 ± 0.67
The selective CRF1 receptor antagonist or a DMSO-dye vehicle were administered by gavage to infant rats at the indicated time prior to infusion of
CRF into the cerebral ventricles. The latency and duration of CRF-induced seizures were determined.
*Significantly different from controls (P = 0.03, Mann–Whitney U-test).
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Table 4
Effects of NBI 27914 on urocortin-induced behavioral phenomena in immature rats
Urocortin dose (nmol) NBI 27914 n Latency of seizures (min) Seizure duration (min)
0.75 – 6 10.3 ± 2.3 98.2 ± 24.0
+ 6 2 = no seizures 18.3 ± 8.7 *
4 = 29.8 ± 13.0
0.15 – 5 1=no seizures 53.0 ± 13.5
4= 11.0 ± 3.6
+ 6 5=no seizures 0
1 = 38 10
CRF0.15 – 17 9.6 ± 1.8 125.3 ± 12.8
The CRF-related peptide, urocortin, which activates both types of CRF receptors, was given via an i.c.v. cannula, at the doses shown. The CRF1
receptor blocker abolished the convulsant effects of urocortin, indicating their mediation via CRF1.
*Significantly different from the same dose of urocortin without NBI 27914 (P < 0.05).
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